Comparison of functional status instruments in HIV-infected adults on effective antiretroviral therapy.

Abstract:

BACKGROUND:The best method for assessment of functional status in human immunodeficiency virus type 1 (HIV-1) infected persons is unknown. OBJECTIVE:We hypothesized that 3 instruments to assess frailty or disability in elderly populations would perform similarly in HIV-1-infected persons. METHODS:HIV-infected subjects 45 to 65 years old with plasma HIV-1 RNA <48 copies/mL were classified prospectively as low, moderate, or high function by Fried's frailty phenotype (FFP), the Short Physical Performance Battery (SPPB), and 400-m walk test. Functional instrument agreement was evaluated by weighted kappa statistic, and relationships with demographic or clinical factors were evaluated by odds ratios (OR). RESULTS:There were 359 participants (85% male, mean age 52 years, mean CD4+ lymphocyte count 551 cells/µL) who were evaluated. Three percent to 8% were low, 31% to 51% were moderate, and 42% to 62% were high function. FFP, SPPB, and 400-m walk test had moderate agreement for functional classification (61%-64%; κ = 0.34-0.41). Across instruments, lower reported physical activity (OR ≯ 5.5; P ≤ .005), no current employment (OR ≯ 4.2; P < .02), arthritis (OR ≯ 6.5; P < .02), neurologic disease (OR ≯ 2.6; P < .05), debilitating pain (OR ≯ 5.4; P < .008), psychiatric disease (OR ≯3.1; P < .03), more comorbidities (OR ≯ 3.6; P ≤ .005), and more non-antiretroviral therapy medications (OR ≯ 3.5; P ≤ .01) were associated with lower function. Current CD4 <200 cells/µL was more likely among low-function (11%) than high-function (2%) persons on FFP (P = .04); other HIV-related characteristics were not significantly different (P > .05) between functional categories on any instrument. CONCLUSIONS:Moderate functional impairment is common among middle-aged HIV-infected persons, with similar frequencies of impairment detected by 3 instruments. Reduction in comorbid disease, increased physical activity, and improved pain symptom management could reduce functional impairment among persons aging with HIV-infection.

journal_name

HIV Clin Trials

journal_title

HIV clinical trials

authors

Erlandson KM,Allshouse AA,Jankowski CM,Duong S,Mawhinney S,Kohrt WM,Campbell TB

doi

10.1310/hct1306-324

subject

Has Abstract

pub_date

2012-11-01 00:00:00

pages

324-34

issue

6

eissn

1528-4336

issn

1945-5771

pii

T442LU2230J42132

journal_volume

13

pub_type

杂志文章
  • Granulocyte-macrophage colony-stimulating factor (GM-CSF) restores allostimulatory function to accessory cells in patients with AIDS.

    abstract:BACKGROUND:Impaired allostimulatory function of dendritic cells in patients with AIDS has been reported previously. Granulocyte-macrophage colony-stimulating factor (GM-CSF) can restore the T-cell stimulatory function in transforming growth factor-beta 1 (TGF-beta 1)-inhibited murine accessory cells. We now report the ...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章

    doi:10.1310/HP8B-NF27-VFWA-80YX

    authors: Bernstein ZP,Brooks SP,Chanan-Khan A,Gollnick SO,Gilbert MJ,Miller KC,Tomasi TB

    更新日期:2002-05-01 00:00:00

  • Missing scheduled visits in the outpatient clinic as a marker of short-term admissions and death.

    abstract:INTRODUCTION:It is not uncommon for patients with HIV infection to miss scheduled visits in outpatient clinics without justifying the failure to appear or reschedule the appointment. Few studies have assessed the impact of inconsistent follow-ups on resource use and disease outcomes in this patient population. OBJECTI...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/hct1305-289

    authors: Colubi MM,Pérez-Elías MJ,Elías L,Pumares M,Muriel A,Zamora AM,Casado JL,Dronda F,López D,Moreno S,SEAD Study Group.

    更新日期:2012-09-01 00:00:00

  • Immune response after a single dose of the 2010/11 trivalent, seasonal influenza vaccine in HIV-1-infected patients and healthy controls.

    abstract:BACKGROUND:Immune response rates following influenza vaccination are often lower in HIV-infected individuals. Low vitamin D levels were correlated with weak immune response in cancer patients and are known to be lower in HIV-infected patients. METHODS:Diagnostic study to determine immune response against the H1N1v com...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/hct1404-175

    authors: Bickel M,Lassmann C,Wieters I,Doerr HW,Herrmann E,Wicker S,Brodt HR,Stephan C,Allwinn R,Jung O

    更新日期:2013-07-01 00:00:00

  • Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone.

    abstract:PURPOSE:Treatment options for HIV-associated lipodystrophy syndrome (HALS) remain limited. The objective of this randomized open-label study was to compare three emerging therapies, rosiglitazone, pravastatin, and growth hormone alone and together, in men and women with HALS. METHOD:Sixty-four subjects received daily ...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1310/hct0904-254

    authors: Macallan DC,Baldwin C,Mandalia S,Pandol-Kaljevic V,Higgins N,Grundy A,Moyle GJ

    更新日期:2008-07-01 00:00:00

  • HIV production from purified monocytes isolated from antiretroviral-naïve and protease inhibitor-treated HIV-1-infected patients.

    abstract:PURPOSE:We obtained peripheral blood monocytes from HIV-1-infected patients and differentiated them into macrophages in vitro to investigate the contribution of purified monocytes to plasma viremia in HIV-infected patients. METHOD:We compared the production of HIV-1 from purified monocytes isolated from patients who w...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/EF26-V3PC-AG5X-FCF4

    authors: Kazanjian P,Adams D,Tate S,Newman G

    更新日期:2002-11-01 00:00:00

  • Can Probiotics Reduce Inflammation and Enhance Gut Immune Health in People Living with HIV: Study Designs for the Probiotic Visbiome for Inflammation and Translocation (PROOV IT) Pilot Trials.

    abstract:OBJECTIVES:Despite substantial improvements in HIV outcomes with combination antiretroviral therapy (cART), morbidity and mortality remain above population norms. The gut mucosal immune system is not completely restored by cART, and the resultant microbial translocation may contribute to chronic inflammation, inadequat...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1080/15284336.2016.1184827

    authors: Kim CJ,Walmsley SL,Raboud JM,Kovacs C,Coburn B,Rousseau R,Reinhard R,Rosenes R,Kaul R

    更新日期:2016-07-01 00:00:00

  • Resistance to antiretroviral agents in individuals with HIV-1 non-B subtypes.

    abstract::Naturally occurring polymorphisms at positions involved in resistance to antiretroviral agents are frequently seen in HIV-1 non-B subtypes. Although they do not seem to affect significantly the susceptibility to antiretroviral drugs in vitro, they may facilitate the selection of different pathways and/or a more rapid ...

    journal_title:HIV clinical trials

    pub_type: 杂志文章,评审

    doi:10.1310/7bwp-0x7f-nxna-qrnp

    authors: Holguín A,Soriano V

    更新日期:2002-09-01 00:00:00

  • Factors associated with complete adherence to HIV combination antiretroviral therapy.

    abstract:PURPOSE:To assess factors associated with adherence, particularly pill burden, to combination antiretroviral therapy (cART) using multivariate models. METHOD:A cross-sectional survey of US adults with a self-reported diagnosis of HIV/AIDS was conducted between April and May 2007. Respondents on a cART regimen of at le...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/hct1202-71

    authors: Juday T,Gupta S,Grimm K,Wagner S,Kim E

    更新日期:2011-03-01 00:00:00

  • Epidemiological and clinical features of pregnant women with HIV: a 21-year perspective from a highly specialized regional center in southern Italy.

    abstract:PURPOSE:To analyze the changes over two decades in HIV-infected pregnant women followed at a highly specialized regional center for antenatal care in southern Italy. METHOD:Since 1985, all HIV-infected pregnant women attending our center have been monitored using progressively updated protocols. RESULTS:By December 2...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/hct0901-36

    authors: Martinelli P,Agangi A,Sansone M,Maruotti GM,Buffolano W,Paladini D,Pizzuti R,Floridia M

    更新日期:2008-01-01 00:00:00

  • Cerebral function in perinatally HIV-infected young adults and their HIV-uninfected sibling controls.

    abstract:BACKGROUND:Perinatally acquired HIV-infected (PaHIV) young adults undergo neurodevelopment in the presence of HIV infection and antiretroviral therapy, which may lead to neurocognitive (NC) impairment. Knowledge of NC function in this group is sparse and control data lacking. We compared cerebral function in young adul...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1179/1528433614Z.0000000003

    authors: Ashby J,Foster C,Garvey L,Wan T,Allsop J,Paramesparan Y,Taylor-Robinson SD,Fidler S,Winston A

    更新日期:2015-03-01 00:00:00

  • Efficacy of an educational and counseling intervention on adherence to highly active antiretroviral therapy: French prospective controlled study.

    abstract:PURPOSE:The objective was to evaluate the impact of an intervention for improving adherence to antiretroviral therapies (HAART) in HIV-infected patients. METHOD:We designed a prospective, controlled, randomized trial to assess the impact of an educational and counseling intervention in addition to standard of care. At...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1310/brbv-3941-h1pp-ndry

    authors: Pradier C,Bentz L,Spire B,Tourette-Turgis C,Morin M,Souville M,Rebillon M,Fuzibet JG,Pesce A,Dellamonica P,Moatti JP

    更新日期:2003-03-01 00:00:00

  • Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers.

    abstract:PURPOSE:To characterize the steady-state pharmacokinetic combination of the nonpeptidic protease inhibitor tipranavir (TPV) with ritonavir (RTV) in 95 healthy adult volunteers, a phase 1, single-center, open-label, randomized, parallel-group trial was conducted. METHOD:Participants received 250-mg self-emulsifying dru...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1310/RRX7-49ME-27V7-MWWV

    authors: MacGregor TR,Sabo JP,Norris SH,Johnson P,Galitz L,McCallister S

    更新日期:2004-11-01 00:00:00

  • Tuberculosis and HIV infection: epidemiology, immunology, and treatment.

    abstract::Tuberculosis and HIV have combined to present a major threat to global public health. Each disease has a negative effect on the other, and mortality in patients with both tuberculosis and HIV is higher than that caused by either condition alone. In regions such as sub-Saharan Africa, as many as a third or more of all ...

    journal_title:HIV clinical trials

    pub_type: 杂志文章,评审

    doi:10.1310/TUNH-UAKU-N0E4-1PXF

    authors: Schluger NW,Burzynski J

    更新日期:2001-07-01 00:00:00

  • Efficacy and safety of stavudine plus didanosine in asymptomatic HIV-infected children with plasma HIV RNA below 50,000 copies per milliliter.

    abstract:BACKGROUND:Simple antiretroviral drug combinations might provide a comparable benefit to standard triple regimens in patients with mild HIV disease, because poor adherence and toxicities often compromise the sustained benefit of the latest triple regimens, especially when protease inhibitors are used. Bad adherence is ...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1310/FAJF-7A8G-QAR4-Q0X5

    authors: de Mendoza C,Ramos JT,Ciria L,Fortuny C,García FJ,de José MI,Asensi F,Soriano V

    更新日期:2002-01-01 00:00:00

  • Darier disease associated with HIV infection: a case report.

    abstract::AIDS is characterized with immune dysregulation and depletion of CD4+ T cells and increased vulnerability to different pathological conditions, including many dermatoses. The present report describes features of Darier disease (DD) in an HIV-positive patient. The subject of this report was a 45-year old Ghanaian man r...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/hct1201-48

    authors: Emadi SN,Izadi M,Poursaleh Z,Akhavan-Moghaddam J,Barikbin B,Emadi SE

    更新日期:2011-01-01 00:00:00

  • Telmisartan increases vascular reparative capacity in older HIV-infected adults: a pilot study.

    abstract:BACKGROUND:Endothelial progenitor cells (EPCs) are bone marrow-derived cells that contribute to vascular repair. EPCs may be reduced in HIV-infected (HIV+) persons, contributing to cardiovascular disease (CVD). Telmisartan is an angiotensin receptor blocker that increases EPCs in HIV-uninfected adults. OBJECTIVE:To as...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1080/15284336.2016.1234222

    authors: Lake JE,Seang S,Kelesidis T,Currier JS,Yang OO

    更新日期:2016-11-01 00:00:00

  • Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States.

    abstract:PURPOSE:A comprehensive study comparing the costs and efficacies of darunavir/ritonavir 800/100 mg qd and the other ritonavir-boosted (/r) protease inhibitors (PIs) recommended for treatment-naïve individuals with HIV-1 infection would help health care decision makers identify the value of each boosted PI. METHODS:A c...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/hct1103-133

    authors: Brogan AJ,Mrus J,Hill A,Sawyer AW,Smets E

    更新日期:2010-05-01 00:00:00

  • Clinically stable treatment-experienced adults receiving tenofovir and didanosine.

    abstract:METHOD:Analysis of virological, immunological, and clinical data over 24 weeks of treatment of drug-experienced patients administered didanosine (ddI) and tenofovir (TDF) plus either PI or NNRTI (17 patients) compared to 14 patients on ddI plus lamivudine and to 19 patients on ddI plus stavudine. RESULTS:Patients trea...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章

    doi:10.1310/0B0R-J1LP-KQPF-43HB

    authors: Di Biagio A,Beltrame A,Cenderello G,Ferrea G,De Maria A

    更新日期:2006-01-01 00:00:00

  • Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients.

    abstract:OBJECTIVE:To describe baseline and emergent HIV-1 resistance to elvitegravir/ cobicistat/emtricitabine/tenofovir DF (EVG/COBI/FTC/TDF) and ritonavir-boosted atazanavir/emtricitabine/tenofovir DF (ATV+RTV+FTC/TDF) in HIV-1-infected, treatment-naïve subjects through 144 weeks. METHOD:This was a randomized, double-blind,...

    journal_title:HIV clinical trials

    pub_type: 杂志文章,随机对照试验

    doi:10.1310/hct1505-218

    authors: Kulkarni R,Abram ME,McColl DJ,Barnes T,Fordyce MW,Szwarcberg J,Cheng AK,Miller MD,White KL

    更新日期:2014-09-01 00:00:00

  • Characteristics associated with virologic failure in high-risk HIV-positive participants with prior failure: a post hoc analysis of ACTG 5251.

    abstract:UNLABELLED:Patients with prior virologic failure (VF) are at an increased risk of subsequent failure, emergence of resistance, and death. This analysis identifies outcomes and correlates of VF in a high-risk population. METHODS:A5251 was designed to evaluate an enhanced adherence counseling intervention delivered by n...

    journal_title:HIV clinical trials

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1080/15284336.2016.1189754

    authors: Robbins GK,Cohn SE,Harrison LJ,Smeaton L,Moran L,Rusin D,Dehlinger M,Flynn T,Lammert S,Wu AW,Safren SA,Reynolds NR

    更新日期:2016-07-01 00:00:00

  • Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients.

    abstract:PURPOSE:The objectives of this study were to determine the prevalence of osteopenia and the factors associated with its presence in HIV-infected patients under highly active antiretroviral therapy (HAART) and to assess the changes of bone mineral density (BMD) in a population followed prospectively. METHOD:BMD was ass...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/4X0H-UVMJ-BHYW-CPFB

    authors: Fernández-Rivera J,García R,Lozano F,Macías J,García-García JA,Mira JA,Corzo JE,Gómez-Mateos J,Rueda A,Sánchez-Burson J,Pineda JA

    更新日期:2003-09-01 00:00:00

  • Determinants of participation in HIV clinical trials: the importance of patients' trust in their provider.

    abstract:PURPOSE:To investigate the factors that contribute to willingness to participate in HIV clinical trials and to determine the impact of a brief intervention on willingness to participate. METHODS:115 consecutive outpatients receiving HIV primary care participated in this prospective study. Each patient completed a ques...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/hct1002-104

    authors: Volkmann ER,Claiborne D,Currier JS

    更新日期:2009-03-01 00:00:00

  • Sustained efficacy of nevirapine in combination with two nucleoside analogues in the treatment of HIV-infected patients: a 48-week retrospective multicenter study.

    abstract:BACKGROUND:Nevirapine, a nonnucleoside analogue, has demonstrated suppression of human immunodeficiency virus (HIV) replication alone and in combination therapy. However, the durable suppression of HIV with nevirapine when used along with other nucleosides in HIV-infected patients who are treated in clinical practice n...

    journal_title:HIV clinical trials

    pub_type: 杂志文章,多中心研究

    doi:10.1310/4nb4-1gx6-4xvk-pbgl

    authors: Allan PS,Arumainayagam J,Harindra V,Tobin J,Browning M,Yoganathan K,Wade A,Das S

    更新日期:2003-07-01 00:00:00

  • Prevalence of CCR5-tropic HIV-1 among treatment-experienced individuals in Spain.

    abstract:OBJECTIVE:To determine the prevalence of CCR5-tropic HIV-1 among treatment-experienced patients in Spain. DESIGN:Epidemiologic, cross-sectional, and non-interventional study between January and June 2008 in HIV-1-infected patients in Spain. METHODS:A total of 485 treatment-experienced patients from across Spainand wi...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/hct1006-394

    authors: Moreno,Clotet,Sarría,Ortega,Leal,Rodriguez-Arrondo,Sánchez-de la Rosa,Allegro Study Group.

    更新日期:2009-11-01 00:00:00

  • Improved survival in HIV-associated diffuse large B-cell lymphoma with the addition of rituximab to chemotherapy in patients receiving highly active antiretroviral therapy.

    abstract:PURPOSE:Recent trials suggest serious toxicity in HIV-associated non-Hodgkin's lymphoma (NHL) with rituximab (R) and chemotherapy (CT), offsetting the benefit of rituximab. METHOD:We retrospectively reviewed experience with CHOP-R vs. CT in 40 patients with HIV-associated diffuse large B-cell lymphoma (DLBCL) diagnose...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/hct0803-132

    authors: Ezzat H,Filipenko D,Vickars L,Galbraith P,Li C,Murphy K,Montaner JS,Harris M,Hogg RS,Vercauteren S,Leger CS,Zypchen L,Leitch HA

    更新日期:2007-05-01 00:00:00

  • Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients.

    abstract:PURPOSE:To assess the virologic and immunologic response to a boosted double-protease inhibitor (PI) regimen of highly pretreated patients infected with HIV-1 and to examine the role of PI resistance and concentration of serum saquinavir. METHOD:In an open-label prospective study, lopinavir/ritonavir, saquinavir-sgc, ...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章

    doi:10.1310/HAG3-8YA5-UDQC-36NX

    authors: Smith GH,Boulassel MR,Klien M,Gilmore N,MacLeod J,LeBlanc R,René P,Routy JP,Lalonde RG

    更新日期:2005-03-01 00:00:00

  • Database-supported teleconferencing: an additional clinical mentoring tool to assist a multinational company HIV/AIDS treatment program in Africa.

    abstract:BACKGROUND:The lack of human resources for health is presently recognized as a major factor limiting scale-up of antiretroviral treatment (ART) programs in resourcelimited settings. The mobilization of public and private partners, the decentralization of care, and the training of non-HIV specialist nurses and general p...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/hct0705-255

    authors: Clevenbergh P,Van der Borght SF,van Cranenburgh K,Janssens V,Kitenge Lubangi C,Gahimbaza L,Lange JM,Rinke de Wit TF,Rijckborst H

    更新日期:2006-09-01 00:00:00

  • Monthly unannounced pill counts for monitoring HIV treatment adherence: tests for self-monitoring and reactivity effects.

    abstract:BACKGROUND:Unannounced home-based pill counts conducted in person or on the telephone are reliable and valid for monitoring medication adherence. However, expecting to have one's pills counted, organizing medications for pill counts, and increased attention from the person conducting the pill counts may have reactive e...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章

    doi:10.1310/hct1106-325

    authors: Kalichman SC,Amaral C,Swetsze C,Eaton L,Kalichman MO,Cherry C,Detorio M,Caliendo AM,Schinazi RF

    更新日期:2010-11-01 00:00:00

  • Randomized, placebo-controlled trial of product R, a peptide-nucleic acid immunomodulator, in the treatment of adults infected with HIV.

    abstract:OBJECTIVE:The efficacy of Product R, a nontoxic peptide-nucleic acid, was tested in 43 HIV-infected adults naïve to antiretroviral therapy. METHOD:Patients were randomized to receive Product R (21 patients) or placebo (22 patients). Dosage was two 1 mL subcutaneous injections daily on days 1-14, followed by 1 mL daily...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1310/N34A-653T-ABF5-8Q1R

    authors: Levett PN,Hirschman SZ,Roach TC,Broome H,Alexander RJ,Fraser HS

    更新日期:2002-07-01 00:00:00

  • Failure to identify HIV-infected individuals in a clinical trial using a single HIV rapid test for screening.

    abstract:BACKGROUND:In the HIV Prevention Trials Network (HPTN) 061 study, 8 (2.3%) of 348 HIV-infected participants identified as HIV uninfected at study enrollment using a single HIV rapid test for screening were found to be HIV infected after additional testing. OBJECTIVES:To evaluate the performance of different HIV assays...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章

    doi:10.1310/hct1502-62

    authors: Piwowar-Manning E,Fogel JM,Laeyendecker O,Wolf S,Cummings V,Marzinke MA,Clarke W,Breaud A,Wendel S,Wang L,Swanson P,Hackett J Jr,Mannheimer S,Del Rio C,Kuo I,Harawa NT,Koblin BA,Moore R,Blankson JN,Eshleman SH

    更新日期:2014-03-01 00:00:00